Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Fase 3-onderzoek naar de werkzaamheid en veiligheid van uit menselijk plasma afgeleid antitrombine (Atenativ) bij heparine-resistente patiënten die een hartoperatie moeten ondergaan waarvoor een cardiopulmonale bypass nodig is

23 september 2026 bijgewerkt door: Octapharma

Fase 3, dubbelblinde, placebogecontroleerde, multicentrische studie naar de werkzaamheid en veiligheid van uit menselijk plasma afgeleid antitrombine (Atenativ) bij heparine-resistente patiënten die een hartoperatie moeten ondergaan die een cardiopulmonaire bypass noodzakelijk maakt

The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

120

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • British Columbia
      • New Westminster, British Columbia, Canada, V3L0A4
        • Werving
        • Royal Columbian Hospital
    • Ontario
      • Kingston, Ontario, Canada, K7L2V7
        • Werving
        • Kingston Health Sciences Centre
      • Toronto, Ontario, Canada, M5G2C4
        • Nog niet aan het werven
        • Toronto General Hospital
    • Quebec
      • Montreal, Quebec, Canada, H1T1C8
        • Werving
        • Montreal Heart Institute
      • Reims, Frankrijk
        • Beëindigd
        • CHU de Reims, Hôpital Robert Debré
      • Rennes, Frankrijk
        • Ingetrokken
        • CHU de Rennes
      • Kaunas, Litouwen
        • Beëindigd
        • Hospital of Lithuanian university of Health sciences Kauno Klinikos
      • Vilnius, Litouwen
        • Werving
        • Vilnius University hospital Santaros Klinikos
      • Innsbruck, Oostenrijk
        • Werving
        • University Hospital Innsbruck
      • Vienna, Oostenrijk
        • Werving
        • Vienna General Hospital AKH, Medical University of Vienna
      • Bucharest, Roemenië
        • Werving
        • Institute for Cardiovascular Diseases C.C. Iliescu
      • Kamenitz, Servië
        • Werving
        • Institute of Cardiovascular Diseases Vojvodina
      • Ljubljana, Slovenië
        • Werving
        • University Medical Centre Ljubljana
      • Brno, Tsjechië
        • Werving
        • Center of Cardiovascular and Transplant Surgery
      • Prague, Tsjechië
        • Beëindigd
        • Institute for Clinical and Experimental Medicine
      • Cambridge, Verenigd Koninkrijk
        • Werving
        • Royal Papworth Hospital
      • Coventry, Verenigd Koninkrijk
        • Werving
        • University Hospital Coventry and Warwickshire
      • Middlesbrough, Verenigd Koninkrijk
        • Werving
        • The James Cook University Hospital
    • California
      • Stanford, California, Verenigde Staten, 94305-5101
        • Werving
        • Stanford University School of Medicine
    • Florida
      • Miami, Florida, Verenigde Staten, 33136
        • Werving
        • University of Miami
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Werving
        • Massachusetts General Hospital
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27710-1000
        • Werving
        • Duke University Medical Center
      • Winston-Salem, North Carolina, Verenigde Staten, 27157
        • Werving
        • Atrium Health Wake Forest Baptist
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44195
        • Werving
        • Cleveland Clinic
      • Columbus, Ohio, Verenigde Staten, 43214
        • Werving
        • The Ohio State University
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • Werving
        • OU Health University of Oklahoma Medical Center
    • Texas
      • Dallas, Texas, Verenigde Staten, 75390
        • Werving
        • University of Texas Southwestern Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 85 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Planned cardiac surgery with CPB
  2. Heparin-resistant patients (pre-CPB Hemochron ACT less than 480 s in the measurement taken between 2-5 minutes following intravenous administration of 500 U/kg UFH)
  3. Patients between 18 and 85 years of age, inclusive
  4. Freely given written or electronic informed consent
  5. In female patients of childbearing potential, a pre-existing negative pregnancy test within 14 days prior to surgery

Exclusion Criteria:

  1. Receiving, or have received within the timeframes specified, one or more of the following medications prior to the start of surgery:

    1. vitamin K antagonists (within 3 days)
    2. direct oral anticoagulants (within 2 days)
    3. thienopyridines (ticlopidine within 14 days, prasugrel within 7 days, or clopidogrel within 5 days), unless platelet function is satisfactory according to local standard of care assessment
    4. ticagrelor (within 5 days), unless platelet function is satisfactory according to local standard of care assessment
    5. glycoprotein IIb/IIIa antagonist (within 24 hours)
  2. Pre-existing coagulopathy, a history of bleeding problems, or a laboratory-diagnosed bleeding disorder (e.g., von Willebrand disease, platelet disorder)

  3. Renal insufficiency, defined as serum creatinine level >2.0 mg/dL

  4. Thrombocytosis, defined as platelet count >400,000 per μL

  5. Known hypersensitivity or allergic reaction to antithrombin or any of the excipients in Atenativ, i.e., human albumin, sodium chloride, acetyl tryptophan, caprylic acid

  6. History of anaphylactic reaction(s) to blood or blood components

  7. Refusal to receive transfusion of blood or blood-derived products

  8. Current participation in another interventional clinical trial or previous participation in the current trial

  9. Treatment with any IMP within 30 days prior to screening visit

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Low-dose Atenativ

Patients will receive a single bolus of 30 international units (IU)/kg body weight (BW) Atenativ.

A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma

Experimenteel: High-dose Atenativ

Patients will receive a single bolus of 60 international units (IU)/kg body weight (BW) Atenativ.

A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma

Placebo-vergelijker: Placebo

Patients will receive a saline bolus dose

Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Restoring heparin responsiveness
Tijdsspanne: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

The percentage of patients in each group in whom no further therapy containing antithrombin (i.e. frozen plasma or other antithrombin concentrates) is needed for restoring pre-CPB heparin responsiveness after administration of Atenativ or placebo, and for maintaining it during CPB

During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Amounts of further therapy for restoring heparin responsiveness
Tijdsspanne: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

The comparison between the amounts of further therapy containing antithrombin (i.e., FP or antithrombin concentrates) needed for restoring pre-CPB heparin responsiveness, after administration of Atenativ or placebo, and for maintaining it during CPB

During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
Change in activated clotting time (ACT) values
Tijdsspanne: Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion

The comparison between the change in ACT values following infusion of each of the Atenativ doses and placebo

Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
Change in antithrombin plasma levels
Tijdsspanne: Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion

The comparison between the change in antithrombin plasma levels following infusion of each of the Atenativ doses and placebo

Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
Change in heparin usage
Tijdsspanne: From end of IMP infusion to the end of surgery

The comparison between heparin usage following the infusion of each of the Atenativ doses and infusion of placebo

From end of IMP infusion to the end of surgery
FP unit use
Tijdsspanne: From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first

The comparison between the number of units of FP transfused for reasons other than restoring or maintaining heparin responsiveness, both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
Amounts of further antithrombin concentrate for maintaining heparin responsiveness
Tijdsspanne: From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first

The comparison between postoperative use of antithrombin concentrates for reasons other than restoring heparin responsiveness (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first)

From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
Transfusion of allogenic blood products
Tijdsspanne: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between transfusion of other allogeneic blood products (e.g., red blood cells [RBCs], platelets, cryoprecipitate, whole blood, albumin, other transfusion), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
Administration of coagulation factor concentrates
Tijdsspanne: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between administration of coagulation factor concentrates (fibrinogen concentrate, factor XIII concentrate, recombinant activated factor VII, other therapy)", both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
Administration of other haemostatic-relevant therapies
Tijdsspanne: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between administration of other haemostatic-relevant therapies (i.e., tranexamic acid, aminocaproic acid, protamine, other therapies), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
Postoperative chest tube drainage
Tijdsspanne: From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between postoperative chest tube drainage volume at 24 hours after the start of Atenativ or placebo infusion, and the comparison between total chest tube drainage volume until discharge or 7 days after surgery, whichever comes first

From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
Need for reoperation due to bleeding
Tijdsspanne: 24 hours after the start of IMP infusion

Comparison of the need for reoperation for bleeding, including description of the cause of bleeding (surgical vs. non-surgical)

24 hours after the start of IMP infusion
Cell saver volume
Tijdsspanne: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

The comparison between cell saver volume until the end of surgery

During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
Adverse events
Tijdsspanne: From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first

Incidence of adverse events, including all related and non-related, non-serious adverse events

From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
Serious adverse events
Tijdsspanne: From the start of IMP infusion until 28 days after IMP administration

Incidence of serious adverse events

From the start of IMP infusion until 28 days after IMP administration
Survival status
Tijdsspanne: At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration

Number of patients surviving in all three cohorts

At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
Red Blood Cell count
Tijdsspanne: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
White Blood Cell count
Tijdsspanne: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
Haemoglobin levels
Tijdsspanne: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
Haematocrit
Tijdsspanne: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
Platelet count
Tijdsspanne: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

21 augustus 2024

Primaire voltooiing (Geschat)

1 maart 2028

Studie voltooiing (Geschat)

1 maart 2028

Studieregistratiedata

Eerst ingediend

17 oktober 2023

Eerst ingediend dat voldeed aan de QC-criteria

17 oktober 2023

Eerst geplaatst (Werkelijk)

23 oktober 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 september 2026

Laatste update ingediend die voldeed aan QC-criteria

23 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren